Intervention

Spironolactone

ClinicalTrials.gov intervention label

Clinical trials66

Recruiting5

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVDNCT03593317 · 2024-12-20

Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic HyperaldosteronismNCT07328230 · 2022-08-01

Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)NCT05092984 · 2022-06-22

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection FractionNCT02901184 · 2017-11-23

Spironolactone for Pulmonary Arterial HypertensionNCT01712620 · 2014-01-10

Determination of Drug Levels for Pharmacotherapy of Heart FailureNCT06035978 · 2024-03-01

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1NCT06004830 · 2023-11-06

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)NCT06005259 · 2023-10-01

Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With SpironolactoneNCT06641284 · 2023-10-01

Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary AldosteronismNCT05814770 · 2023-05-01

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early DementiaNCT04522739 · 2022-09-06

Spironolactone in CKD Enabled by Chlorthalidone: PILOTNCT05222191 · 2022-02-01

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving SpironolactoneNCT04676646 · 2021-03-08

Pharmacogenetics of Torasemide and Spironolactone in Hypertension TreatmentNCT06413082 · 2021-02-15

Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant HypertensionNCT04331691 · 2020-11-16

A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart FailureNCT03984591 · 2020-11-01

ENROLLING_BY_INVITATION

Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart FailureNCT04618601 · 2020-10-20

The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart FailureNCT04455178 · 2020-09-23

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR TrialNCT04190433 · 2020-09-01

Spironolactone Versus Indapamide in Obese and Hypertensive PatientsNCT03626506 · 2019-02-13

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum PotassiumNCT03682497 · 2018-11-01

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-OnNCT03597035 · 2018-07-17

Spironolactone Therapy in Chronic Stable Right HF TrialNCT03344159 · 2018-04-01

The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.NCT04393493 · 2017-07-01

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney DiseaseNCT03071263 · 2017-01-23

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen ExcessNCT01422759 · 2016-12-09

Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial HypertensionNCT02832973 · 2015-09-01

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 DiabetesNCT03174288 · 2015-08-01

Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety StudyNCT02299726 · 2015-05-01

Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart FailureNCT02235077 · 2014-12-30

Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD TrialNCT02285920 · 2014-11-01

Biomarker Guided Therapies in Stage A/B Heart FailureNCT02230891 · 2014-10-01

Tissue Sodium in Pre-hypertensive PatientsNCT02236520 · 2014-09-01

A Study of LY2623091 in Participants With High Blood PressureNCT02194465 · 2014-08-01

Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKDNCT02502981 · 2014-06-01

High-Dose Aldactone for Treatment of Diuretic Resistant Heart FailureNCT02429388 · 2014-05-01

Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With NormoalbuminuriaNCT02040441 · 2014-03-01

L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRDNCT01855334 · 2013-09-01

Mineralocorticoid Receptor Antagonists in End Stage Renal DiseaseNCT01691053 · 2012-12-01

Resistant Hypertension Optimal TreatmentNCT01643434 · 2012-08-01

Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney DiseaseNCT01598740 · 2012-06-01

Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 DiabetesNCT01586442 · 2012-03-01

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic NephropathyNCT01488877 · 2012-01-01

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial HypertensionNCT01468571 · 2011-07-01

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney DiseaseNCT01345656 · 2011-05-09

The Effect of Amiloride and Spironolactone in Patients With HypertensionNCT01388088 · 2010-09-01

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular VariablesNCT01195805 · 2010-08-01

Optimum Treatment for Drug-Resistant HypertensionNCT02369081 · 2009-05-01

Aldosterone in Diabetic NephropathyNCT00870402 · 2009-03-01

Mineralocorticoid Receptor and Obesity Induced Cardiovascular ComplicationsNCT01406015 · 2009-02-01

The Effect of Amiloride and Spironolactone in Healthy PersonsNCT00857909 · 2009-01-01

Etiology of Sleep Apnea-related Hyperaldosteronism - BP TreatmentNCT01897727 · 2009-01-01

Role of Mineralocorticoid Receptor in Diabetic Cardiovascular DiseaseNCT00865124 · 2008-09-01

SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)NCT00604006 · 2008-09-01

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal DiseaseNCT00548912 · 2007-10-01

Aldosterone Blockade in Heart FailureNCT00523757 · 2007-08-01

The Efficacy of Spironolactone in Patients With Resistant HypertensionNCT00430794 · 2007-03-01

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs AloneNCT00391846 · 2006-10-01

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionNCT00094302 · 2006-08-01

Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone TherapyNCT00335413 · 2006-06-01

Common conditions

Leading sponsors

AstraZeneca3 Brigham and Women's Hospital3 Baylor College of Medicine2 Regional Hospital Holstebro2 Steno Diabetes Center Copenhagen2 University of Virginia2 Ahmad Abdullah Salawi1 Bayer1 Bispebjerg Hospital1 Carelon Research1 Chinese Academy of Medical Sciences, Fuwai Hospital1 Dawnmarie DeFazio1 Duke University1 Eli Lilly and Company1 Emory University1

Trial status mix

COMPLETED38

UNKNOWN13

RECRUITING5

WITHDRAWN5

TERMINATED4

ENROLLING_BY_INVITATION1

Phase mix

PHASE425

PHASE218

NA10

PHASE310

PHASE14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.